Akso Health GroupAHG +0.33%36 3-Year RORE % is 31.81 as of Sep. 2025. GuruFocus rates AHG with a GF Score™ of 36/100 and a GF Value™ of $0.47 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 111 Medical Distribution companies, Akso Health Group ranks better than 72.97% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Akso Health Group's 3-Year RORE % for the quarter that ended in Sep. 2025 was 31.81%.
The industry rank for Akso Health Group's 3-Year RORE % or its related term are showing as below:
AHG's 3-Year RORE % is ranked better than 72.97% of 111
companies
in the Medical Distribution industry
Industry Median: 14.45
vs AHG: 31.81
Akso Health Group (NAS:AHG) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Akso Health Group 3-Year RORE % Related Terms
Akso Health Group 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Akso Health Group's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Akso Health Group's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akso Health Group 3-Year RORE % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Akso Health Group's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Akso Health Group's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Sep. 2025 and 3-year before.
Akso Health Group (AHG) has a 3-Year RORE % of 31.81 as of Sep. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Akso Health Group and its competitors. According to the industry distribution chart, Akso Health Group ranks #30 out of 111 companies in the Medical Distribution industry, placing it in the top 27%.
Is Akso Health Group's 3-Year RORE % too high?
Akso Health Group's current 3-Year RORE % is 31.81. The Medical Distribution industry median 3-Year RORE % is 14.45. Akso Health Group's value of 31.81 is 120.1% above this industry median. Based on the distribution chart, Akso Health Group ranks #30 out of 111 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Akso Health Group has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Akso Health Group's 3-Year RORE % compare to ACH and FOCL?
According to the Medical Distribution industry distribution chart, Akso Health Group ranks #30 out of 111 companies for 3-Year RORE %. This puts Akso Health Group in the upper half of its industry. The industry median 3-Year RORE % is 14.45. Akso Health Group's value of 31.81 is 120.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Distribution company?
The median 3-Year RORE % among Medical Distribution companies is 14.45, based on 111 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Akso Health Group's current 3-Year RORE % of 31.81 is 120.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Akso Health Group and its competitors. For the Medical Distribution industry, the median 3-Year RORE % is 14.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Akso Health Group's current 3-Year RORE % is 31.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akso Health Group stock overvalued right now?
Based on GuruFocus' analysis, Akso Health Group (AHG) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.47, compared to a current price of $1.69 — trading 259.6% above its estimated fair value. The current 3-Year RORE % is 31.81 and 120.1% above the Medical Distribution industry median of 14.45. Akso Health Group's overall GF Score™ is 36/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Akso Health Group (AHG), the current 3-Year RORE % is 31.81 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Akso Health Group (AHG) Overvalued in 2026?
Based on GuruFocus' analysis, Akso Health Group stock appears to be overvalued.
The current stock price of $1.69 is trading 259.6% above its estimated GF Value™ of $0.47.
GuruFocus considers Akso Health Group to be Significantly Overvalued.
Key valuation signals for AHG:
3-Year RORE %: 31.81
GF Value™: $0.47 vs. price of $1.69 (259.6% above fair value)
Industry Position: 120.1% above the Medical Distribution median (#30 of 111)
No single metric tells the full story. See the AHG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Akso Health Group is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.
36GF Score
Get the complete analysis for AHG
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AHG has been successfully added to your 
